Advanced Search
Contact | Corporate | Help

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Sponsors:
  • Massachusetts General Hospital
  • Dana-Farber Cancer Institute
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Non-small Cell Lung Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: Erlotinib
Enrollment:
100

Additional information about NCT00567359.


SourceSolution © 2008-2012